MedTrace Logo

The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

NCT06086665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 850

Last updated 2026-02-04

No results posted yet for this study

Summary

1. To evaluate the efficacy and safety of niraparib in Korean women with primary and recurrent epithelial ovarian cancer who underwent niraparib maintenance therapy
2. To evaluate the efficacy and safety of salvage niraparib therapy in Korean women with heavily pretreated epithelial ovarian cancer.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

Niraparib

Niraparib

Sponsors & Collaborators

  • Samsung Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • Gangnam Severance Hospital

    collaborator OTHER

  • Keimyung University Dongsan Medical Center

    collaborator OTHER

  • Kyungpook National University Chilgok Hospital

    collaborator OTHER

  • Seoul St. Mary's Hospital

    collaborator OTHER

  • National Cancer Center, Korea

    collaborator OTHER_GOV

  • Pusan National University Yangsan Hospital

    collaborator OTHER

  • Inje University

    collaborator OTHER

  • Pusan National University Hospital

    collaborator OTHER

  • Asan Medical Center

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2022-10-31
Completion
2022-10-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086665 on ClinicalTrials.gov